alexa Therapeutic Potential Of Ixmyelocel-T, An Expanded Autologous Multicellular Therapy, Derived From Bone Marrow, For Treatment Of Ischemic Cardiovascular Diseases
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference and Exhibition on Clinical & Cellular Immunology
September 29-October 01, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA

Ross Tubo and Kelly Ledford
Accepted Abstracts: J Clin Cell Immunol
DOI: 10.4172/2155-9899.S1.019
Abstract
Avariety of bone marrow derived cell therapies have been utilized to treat ischemic tissue damage and promote more balanced tissue repair under inflammatory conditions. Ixmyelocel-T, is an autologous, culture expanded, bone marrow- derived multicellular therapy which contains MSCs and M2-like macrophages, as well as many of the CD45+ cells found in the bone marrow. MSC and M2-macrophages have been shown to exhibit properties useful for angiogenesis and modulation of tissue repair in response to ischemia. In this study, it was used a rat model of hind limb ischemia to determine the effects of ixmyelocel-T on restoration of blood flow to the ischemic limb. Further, the mechanism(s) for action of ixmyelocel-T in angiogenesis on endothelial cells, by co-culturing with human umbilical vein endothelial cells (HUVEC) in non-contacting Transwell? inserts, in vitro was explored. Co-culture of HUVECs with ixmyelocel-T resulted secretion of a variety of pro- angiogenic factors, eNOS expression and nitric oxide (NO) production, and enhanced migration, proliferation, and branch formation. In TNFα-stimulated HUVECs, ixmyelocel-T co-culture decreased apoptosis and reactive oxygen species generation, increased super oxide dismutase activity, and decreased NFκB activation. Treatment with ixmyelocel-T in a rat model of hind limb ischemia resulted in significantly increased blood flow perfusion and capillary density, gene expression and plasma levels of the anti-inflammatory cytokine IL-10, plasma nitrates, plasma PDGF-BB, VEGF expression, and significantly decreased plasma TBARS. Fluorescently labeled ixmyelocel-T was detected in the ischemic limb up to six weeks after transplantation. Transplanted ixmyelocel-T did not co-localized with CD31+ endothelial cells, but did co-localize with the M2 macrophage marker CD206 in the ischemic tissue suggesting that ixmyelocel-T promotes angiogenesis in a paracrine manner. This data suggests that ixmyelocel-T could be useful for promoting of angiogenesis and tissue repair in ischemic tissue injury and diseas
Biography
Ross Tubo, PhD, is Chief Scientific Officer, Aastrom Biosciences. He has more than twenty years of experience in cell therapy, regenerative medicine, and stem cell biology. He was a pioneer in the research, development, and commercialization of the first autologous cell therapy for articular cartilage repair, known as Carticel. As Vice President of Stem Cell and Chemokine Biology for Genzyme Corporation, he developed a world-class research organization designed to understand the underlying cell and molecular mechanism(s) of action of mesenchymal stem cells (MSCs) in autoimmune disease and cancer. These efforts led to the identification of specific therapeutic targets for treatment of these diseases. He holds a PhD in Cell and Molecular Biology from State University of New York at Buffalo.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version